Coloplast growth in danger: "There is no doubt that Coronavirus will impact the second quarter"
Coloplast overcame a price squeeze in the first quarter and generated 8 percent growth for the 11th quarter in a row. But the Coronavirus outbreak is threatening to throw a spanner in the works in the second quarter of 2020, says the company's financial director.
Denmark's largest medtech company, Coloplast, positively surprised analysts on Thursday by presenting 8 percent organic sales growth for the 11th quarter in a row, despite a price squeeze in France.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
